Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings

  • Adaptimmune Therapeutics plc ADAP revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4).
  • Data will be presented at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.
  • According to the new data from the company's TCR therapy shrunk the tumors of 13 of the 33 evaluable second-line sarcoma patients.
  • The overall response rate was 39.3%, with 41.4% (12/29) for synovial sarcoma; 25.0% (1/4) for myxoid/ round cell liposarcoma (MRCLS).
  • The company said that the initial durability data is encouraging, and the median duration of response has not been reached.
  • On the safety front, afami-cel has been favorable, with mainly low-grade cytokine release syndrome and tolerable/reversible hematologic toxicities.
  • The company plans to file for approval in 2022.
  • Price Action: ADAP shares are up 8.6% at $5.32 during the premarket session on the last check Thursday.

Posted In: BriefscancerBiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.